Literature DB >> 22136892

Pre- and post-dormitum epilepsies: idiopathic generalized epilepsies.

Elena Zambrelli1, Maria Paola Canevini.   

Abstract

Epilepsy and sleep have a profound bidirectional influence. Idiopathic generalized epilepsy (IGE) comprises a fascinating group of syndromes that constitute nearly one-third of all epilepsies. These syndromes are genetically determined and affect otherwise normal people of both sexes and all races. IGE manifests with typical absences, myoclonic jerks, and generalized tonic-clonic seizures, alone or in varying combinations and severity. IGE syndromes are typically modulated by the sleep-wake cycle, and particularly by the sleep-wake transition process, both in terms of the occurrence of seizures and interictal epileptiform discharges (IED), with pronounced susceptibility to sleep deprivation. IGE analysis from the point of view of arousal modulation enhances the concept of a biological continuum existing among IGE syndromes. At the same time, this analysis broaches the problem of syndromic diagnosis and identification of the factors influencing the phenotypic expression of some epileptic phenomena over the course of life with potential bidirectional influences between epileptic manifestations and sleep-wake processes.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22136892     DOI: 10.1016/j.sleep.2011.10.006

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  2 in total

1.  Seizure Activity and Intervention Efficacy Are Shaped by REMnants of Preceding Brain States.

Authors:  Catherine A Christian
Journal:  Epilepsy Curr       Date:  2016 May-Jun       Impact factor: 7.500

2.  Brain State Is a Major Factor in Preseizure Hippocampal Network Activity and Influences Success of Seizure Intervention.

Authors:  Laura A Ewell; Liang Liang; Caren Armstrong; Ivan Soltész; Stefan Leutgeb; Jill K Leutgeb
Journal:  J Neurosci       Date:  2015-11-25       Impact factor: 6.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.